{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:24:26Z","timestamp":1787714666950,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"College Students'' Innovative Training Program","award":["S202310660072,2024106600540,202510660105)"],"award-info":[{"award-number":["S202310660072,2024106600540,202510660105)"]}]},{"name":"Ph.D. Start-Up Fund of Guizhou Medical University","award":["([2020]026)"],"award-info":[{"award-number":["([2020]026)"]}]},{"name":"Science and Technology Fund of Guizhou Provincial Health Commission","award":["gzwkj2023-572"],"award-info":[{"award-number":["gzwkj2023-572"]}]},{"name":"Guizhou Medical University National Foundation Cultivation Project","award":["20NSP007"],"award-info":[{"award-number":["20NSP007"]}]},{"name":"Guizhou Provincial Basic Research Program(Natural Science),","award":["ZK [2021]106"],"award-info":[{"award-number":["ZK [2021]106"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Funct Integr Genomics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10142-026-02019-3","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:08:17Z","timestamp":1787713697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Berberine-associated lipid-inflammatory regulation in atherosclerosis: an integrative transcriptomic, single-cell, and in vivo study"],"prefix":"10.1007","volume":"26","author":[{"given":"Diwei","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-E","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanning","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2019_CR1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41419-024-07166-8","volume":"15","author":"A Ajoolabady","year":"2024","unstructured":"Ajoolabady A et al (2024) Inflammation in atherosclerosis: pathophysiology and mechanisms. Cell Death Dis 15:817. https:\/\/doi.org\/10.1038\/s41419-024-07166-8","journal-title":"Cell Death Dis"},{"key":"2019_CR2","doi-asserted-by":"publisher","first-page":"1485801","DOI":"10.3389\/fimmu.2025.1485801","volume":"16","author":"G Araujo","year":"2025","unstructured":"Araujo G, Valencia LM, Martin-Ozimek A, Soto Y, Proctor SD (2025) Atherosclerosis: from lipid-lowering and anti-inflammatory therapies to targeting arterial retention of ApoB-containing lipoproteins. Front Immunol 16:1485801. https:\/\/doi.org\/10.3389\/fimmu.2025.1485801","journal-title":"Front Immunol"},{"key":"2019_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-026-01450-7","author":"Q Cai","year":"2026","unstructured":"Cai Q et al (2026) Macrophage CCRL2 promotes NLRP3 inflammasome activation to exacerbate atherosclerosis. Cell Mol Immunol. https:\/\/doi.org\/10.1038\/s41423-026-01450-7","journal-title":"Cell Mol Immunol"},{"key":"2019_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag047","author":"L Cai","year":"2026","unstructured":"Cai L et al (2026) Macrophage SBK2 suppresses inflammation and atherosclerosis by NLRP3 phosphorylation. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehag047","journal-title":"Eur Heart J"},{"key":"2019_CR5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1161\/circresaha.120.316770","volume":"127","author":"MAC Depuydt","year":"2020","unstructured":"Depuydt MAC et al (2020) Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics. Circ Res 127:1437\u20131455. https:\/\/doi.org\/10.1161\/circresaha.120.316770","journal-title":"Circ Res"},{"key":"2019_CR6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s44161-023-00295-x","volume":"2","author":"L Dib","year":"2023","unstructured":"Dib L et al (2023) Lipid-associated macrophages transition to an inflammatory state in human atherosclerosis, increasing the risk of cerebrovascular complications. Nat Cardiovasc Res 2:656\u2013672. https:\/\/doi.org\/10.1038\/s44161-023-00295-x","journal-title":"Nat Cardiovasc Res"},{"key":"2019_CR7","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.7150\/thno.30787","volume":"9","author":"X Feng","year":"2019","unstructured":"Feng X et al (2019) Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics. Theranostics 9:1923\u20131951. https:\/\/doi.org\/10.7150\/thno.30787","journal-title":"Theranostics"},{"key":"2019_CR8","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","volume":"25","author":"DM Fernandez","year":"2019","unstructured":"Fernandez DM et al (2019) Single-cell immune landscape of human atherosclerotic plaques. Nat Med 25:1576\u20131588. https:\/\/doi.org\/10.1038\/s41591-019-0590-4","journal-title":"Nat Med"},{"key":"2019_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-026-01249-z","author":"M Galli","year":"2026","unstructured":"Galli M et al (2026) Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies. Nat Rev Cardiol. https:\/\/doi.org\/10.1038\/s41569-026-01249-z","journal-title":"Nat Rev Cardiol"},{"key":"2019_CR10","doi-asserted-by":"publisher","unstructured":"Guo HH et al (2023) Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. Biomed Pharmacother = Biomed Pharmacotherapie 163:114754. https:\/\/doi.org\/10.1016\/j.biopha.2023.114754","DOI":"10.1016\/j.biopha.2023.114754"},{"key":"2019_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41419-023-06206-z","volume":"14","author":"P Hou","year":"2023","unstructured":"Hou P et al (2023) Macrophage polarization and metabolism in atherosclerosis. Cell Death Dis 14:691. https:\/\/doi.org\/10.1038\/s41419-023-06206-z","journal-title":"Cell Death Dis"},{"key":"2019_CR12","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/ptr.5693","volume":"30","author":"M Imenshahidi","year":"2016","unstructured":"Imenshahidi M, Hosseinzadeh H (2016) Berberis vulgaris and berberine: an update review. Phytother Res 30:1745\u20131764. https:\/\/doi.org\/10.1002\/ptr.5693","journal-title":"Phytother Res"},{"key":"2019_CR13","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm1135","volume":"10","author":"W Kong","year":"2004","unstructured":"Kong W et al (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10:1344\u20131351. https:\/\/doi.org\/10.1038\/nm1135","journal-title":"Nat Med"},{"key":"2019_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jare.2024.12.040","volume":"76","author":"WY Lee","year":"2025","unstructured":"Lee WY et al (2025) Evaluating current status of network pharmacology for herbal medicine focusing on identifying mechanisms and therapeutic effects. J Adv Res 76:799\u2013815. https:\/\/doi.org\/10.1016\/j.jare.2024.12.040","journal-title":"J Adv Res"},{"key":"2019_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2025.100220","volume":"27","author":"L Li","year":"2025","unstructured":"Li L, Kar S (2025) Leveraging network pharmacology for drug discovery: integrative approaches and emerging insights. Med Drug Discov 27:100220. https:\/\/doi.org\/10.1016\/j.medidd.2025.100220","journal-title":"Med Drug Discov"},{"key":"2019_CR16","doi-asserted-by":"publisher","first-page":"17374","DOI":"10.1039\/d5sc05395a","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y et al (2025) Decoding the limits of deep learning in molecular docking for drug discovery. Chem Sci 16:17374\u201317390. https:\/\/doi.org\/10.1039\/d5sc05395a","journal-title":"Chem Sci"},{"key":"2019_CR17","doi-asserted-by":"publisher","first-page":"1572197","DOI":"10.3389\/fphar.2025.1572197","volume":"16","author":"D Liu","year":"2025","unstructured":"Liu D, Zhao H, Zhang Y, Hu J, Xu H (2025) Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Front Pharmacol 16:1572197. https:\/\/doi.org\/10.3389\/fphar.2025.1572197","journal-title":"Front Pharmacol"},{"key":"2019_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.841545","volume":"9","author":"MB Lorey","year":"2022","unstructured":"Lorey MB, \u00d6\u00f6rni K, Kovanen PT (2022) Modified lipoproteins induce arterial wall inflammation during atherogenesis. Front Cardiovasc Med 9:841545. https:\/\/doi.org\/10.3389\/fcvm.2022.841545","journal-title":"Front Cardiovasc Med"},{"key":"2019_CR19","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.apsb.2020.03.005","volume":"10","author":"X Ma","year":"2020","unstructured":"Ma X et al (2020) Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe ((-\/-)) mice. Acta Pharm Sin B 10:1769\u20131783. https:\/\/doi.org\/10.1016\/j.apsb.2020.03.005","journal-title":"Acta Pharm Sin B"},{"key":"2019_CR20","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.21037\/atm-20-8106","volume":"9","author":"CY Ma","year":"2021","unstructured":"Ma CY et al (2021) Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-\/-) mice by down-regulating PCSK9 via ERK1\/2 pathway. Annal Transl Med 9:1517. https:\/\/doi.org\/10.21037\/atm-20-8106","journal-title":"Annal Transl Med"},{"key":"2019_CR21","doi-asserted-by":"publisher","unstructured":"Oppi S, L\u00fcscher TF, Stein S (2019) Mouse Models for Atherosclerosis Research\u2014Which Is My Line? 6.https:\/\/doi.org\/10.3389\/fcvm.2019.00046","DOI":"10.3389\/fcvm.2019.00046"},{"key":"2019_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.athplu.2024.12.004","volume":"59","author":"M Palumbo","year":"2025","unstructured":"Palumbo M, Ugolotti M, Zimetti F, Adorni MP (2025) Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: focus on PPARs, LXRs, and PCSK9. Atheroscler Plus 59:39\u201353. https:\/\/doi.org\/10.1016\/j.athplu.2024.12.004","journal-title":"Atheroscler Plus"},{"key":"2019_CR23","doi-asserted-by":"publisher","first-page":"11282","DOI":"10.1038\/s41467-025-67679-4","volume":"16","author":"J Pauli","year":"2025","unstructured":"Pauli J et al (2025) Single cell spatial transcriptomics integration deciphers the morphological heterogeneity of atherosclerotic carotid arteries. Nat Commun 16:11282. https:\/\/doi.org\/10.1038\/s41467-025-67679-4","journal-title":"Nat Commun"},{"key":"2019_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154525","volume":"108","author":"J Peng","year":"2023","unstructured":"Peng J et al (2023) The mechanisms of Qizhu Tangshen formula in the treatment of diabetic kidney disease: network pharmacology, machine learning, molecular docking and experimental assessment. Phytomedicine 108:154525. https:\/\/doi.org\/10.1016\/j.phymed.2022.154525","journal-title":"Phytomedicine"},{"key":"2019_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0092-8674(92)90362-g","volume":"71","author":"AS Plump","year":"1992","unstructured":"Plump AS et al (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343\u2013353. https:\/\/doi.org\/10.1016\/0092-8674(92)90362-g","journal-title":"Cell"},{"key":"2019_CR26","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s40200-024-01482-8","volume":"23","author":"N Saki","year":"2024","unstructured":"Saki N et al (2024) Modification macrophage to foam cells in atherosclerosis disease: some factors stimulate or inhibit this process. J Diabetes Metab Disord 23:1687\u20131697. https:\/\/doi.org\/10.1007\/s40200-024-01482-8","journal-title":"J Diabetes Metab Disord"},{"key":"2019_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1620\/tjem.2025.J036","volume":"267","author":"X Shen","year":"2025","unstructured":"Shen X et al (2025) Berberine improves ox-LDL-induced macrophage efferocytosis dysfunction and alleviates inflammation via the PPAR\u03b3\/LXR\u03b1 pathway. Tohoku J Exp Med 267:185\u2013201. https:\/\/doi.org\/10.1620\/tjem.2025.J036","journal-title":"Tohoku J Exp Med"},{"key":"2019_CR28","doi-asserted-by":"publisher","first-page":"1783475","DOI":"10.3389\/fphar.2026.1783475","volume":"17","author":"N Shi","year":"2026","unstructured":"Shi N, Zhou X, Wu S, Zhang Y (2026) The lipid-modulating effect of berberine in hyperlipidemic ApoE-\/- mice. Front Pharmacol 17:1783475. https:\/\/doi.org\/10.3389\/fphar.2026.1783475","journal-title":"Front Pharmacol"},{"key":"2019_CR29","doi-asserted-by":"publisher","unstructured":"Solnier J et al (2023) Characterization and pharmacokinetic assessment of a new berberine formulation with enhanced absorption in vitro and in human volunteers. Pharmaceutics 15. https:\/\/doi.org\/10.3390\/pharmaceutics15112567","DOI":"10.3390\/pharmaceutics15112567"},{"key":"2019_CR30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s42255-024-01015-w","volume":"6","author":"C Stroope","year":"2024","unstructured":"Stroope C et al (2024) Dysregulated cellular metabolism in atherosclerosis: mediators and therapeutic opportunities. Nat Metab 6:617\u2013638. https:\/\/doi.org\/10.1038\/s42255-024-01015-w","journal-title":"Nat Metab"},{"key":"2019_CR31","doi-asserted-by":"publisher","first-page":"1368950","DOI":"10.3389\/fphar.2024.1368950","volume":"15","author":"A Sun","year":"2024","unstructured":"Sun A et al (2024) Molecular mechanisms, targets and clinical potential of berberine in regulating metabolism: a review focussing on databases and molecular docking studies. Front Pharmacol 15:1368950. https:\/\/doi.org\/10.3389\/fphar.2024.1368950","journal-title":"Front Pharmacol"},{"key":"2019_CR32","doi-asserted-by":"publisher","unstructured":"Torres PHM, Sodero AC, Jofily P, Silva-Jr FP (2019) Key topics in molecular docking for drug design. Int J Mol Sci 20. https:\/\/doi.org\/10.3390\/ijms20184574","DOI":"10.3390\/ijms20184574"},{"key":"2019_CR33","doi-asserted-by":"publisher","first-page":"8255","DOI":"10.1038\/s41467-025-63202-x","volume":"16","author":"K Traeuble","year":"2025","unstructured":"Traeuble K et al (2025) Integrated single-cell atlas of human atherosclerotic plaques. Nat Commun 16:8255. https:\/\/doi.org\/10.1038\/s41467-025-63202-x","journal-title":"Nat Commun"},{"key":"2019_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1161\/atvbaha.125.322198","volume":"46","author":"G Wang","year":"2026","unstructured":"Wang G et al (2026) Distinct roles of PPARs in atherosclerosis. Arterioscler Thromb Vasc Biol 46:68\u201384. https:\/\/doi.org\/10.1161\/atvbaha.125.322198","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2019_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fphar.2020.00223","volume":"11","author":"M Wu","year":"2020","unstructured":"Wu M et al (2020) Effect of berberine on atherosclerosis and gut microbiota modulation and their correlation in High-Fat Diet-Fed ApoE-\/- Mice. Front Pharmacol 11:223. https:\/\/doi.org\/10.3389\/fphar.2020.00223","journal-title":"Front Pharmacol"},{"key":"2019_CR36","doi-asserted-by":"publisher","unstructured":"Wu Y et al (2026) Integrative single-cell analysis reveals endothelial diversity in the vasa vasorum of human atherosclerosis. Commun Biol 9. https:\/\/doi.org\/10.1038\/s42003-026-10095-1","DOI":"10.1038\/s42003-026-10095-1"},{"key":"2019_CR37","doi-asserted-by":"crossref","unstructured":"Zernecke A et al (2023) Integrated single-cell analysis-based classification of vascular mononuclear phagocytes in mouse and human atherosclerosis. Cardiovasc Res 119:1676\u20131689. 10.1093\/cvr\/cvac161%JCardiovascularResearch","DOI":"10.1093\/cvr\/cvac161"},{"key":"2019_CR38","doi-asserted-by":"publisher","first-page":"1490387","DOI":"10.3389\/fimmu.2024.1490387","volume":"15","author":"L Zhang","year":"2024","unstructured":"Zhang L et al (2024) Mechanisms and treatment of atherosclerosis: focus on macrophages. Front Immunol 15:1490387. https:\/\/doi.org\/10.3389\/fimmu.2024.1490387","journal-title":"Front Immunol"},{"key":"2019_CR39","doi-asserted-by":"publisher","first-page":"1540835","DOI":"10.3389\/fphar.2025.1540835","volume":"16","author":"P Zhang","year":"2025","unstructured":"Zhang P et al (2025) Berberine alleviates atherosclerosis by modulating autophagy and inflammation through the RAGE-NF-\u03baB pathway. Front Pharmacol 16:1540835. https:\/\/doi.org\/10.3389\/fphar.2025.1540835","journal-title":"Front Pharmacol"},{"key":"2019_CR41","doi-asserted-by":"publisher","unstructured":"Zhao JV et al (2026) Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization. NPJ Cardiovasc Health 3. https:\/\/doi.org\/10.1038\/s44325-026-00113-w","DOI":"10.1038\/s44325-026-00113-w"},{"key":"2019_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jare.2024.03.020","volume":"69","author":"Y Zheng","year":"2025","unstructured":"Zheng Y et al (2025) PPARs in atherosclerosis: the spatial and temporal features from mechanism to druggable targets. J Adv Res 69:225\u2013244. https:\/\/doi.org\/10.1016\/j.jare.2024.03.020","journal-title":"J Adv Res"},{"key":"2019_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178234","volume":"1007","author":"J Zheng","year":"2025","unstructured":"Zheng J et al (2025) Berberine ameliorates atherosclerosis by inhibiting the phenotypic transition of vascular smooth muscle cells via suppression of the JAK2\/STAT3 signaling pathway. Eur J Pharmacol 1007:178234. https:\/\/doi.org\/10.1016\/j.ejphar.2025.178234","journal-title":"Eur J Pharmacol"}],"container-title":["Functional & Integrative Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-026-02019-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10142-026-02019-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-026-02019-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:08:21Z","timestamp":1787713701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10142-026-02019-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2019"],"URL":"https:\/\/doi.org\/10.1007\/s10142-026-02019-3","relation":{},"ISSN":["1438-793X","1438-7948"],"issn-type":[{"value":"1438-793X","type":"print"},{"value":"1438-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During manuscript preparation, ChatGPT (OpenAI, GPT-5.5 Thinking) was used for language editing, improvement of clarity, and refinement of academic expression. The authors reviewed and edited all AI-assisted text and take full responsibility for the accuracy, integrity, and final content of the manuscript.","order":2,"name":"Ethics","label":"Use of generative AI","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No potential conflict of interest was reported by the author(s).","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"233"}}